{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Tislelizumab", "query": { "intervention": "Intravenous Tislelizumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Tislelizumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T09:50:54.334Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04746924", "title": "A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 669, "start_date": "2021-05-24", "completion_date": "2026-03-18", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04746924" }, { "nct_id": "NCT05604560", "title": "A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "SX-682", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lei Zheng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-11-08", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 2, "location_summary": "Baltimore, Maryland • San Antonio, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05604560" }, { "nct_id": "NCT04294160", "title": "A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRAF V600 Colorectal Cancer" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "LTT462", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "LXH254", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "Spartalizumab", "type": "BIOLOGICAL" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2020-07-22", "completion_date": "2024-09-25", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04294160" }, { "nct_id": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors", "Advanced Non-squamous Non-small-cell Lung Cancer", "Advanced Colorectal Cancer", "Advanced Pancreatic Ductal Adenocarcinoma", "Advanced Gastric Cancer", "Advanced Gastroesophageal Junction Cancer", "Advanced Esophageal Adenocarcinoma" ], "interventions": [ { "name": "BGB-53038", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2024-12-13", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 4, "location_summary": "Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06585488" }, { "nct_id": "NCT05238883", "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Renal Cell Carcinoma", "Melanoma", "Sarcoma", "Testicular Germ Cell Tumor", "Cervical Cancer", "Mesothelioma", "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "HFB200301", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HiFiBiO Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-03-10", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238883" }, { "nct_id": "NCT03412773", "title": "A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 684, "start_date": "2017-12-18", "completion_date": "2023-12-14", "has_results": true, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Orange, California + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412773" }, { "nct_id": "NCT05981703", "title": "A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Solid Tumor" ], "interventions": [ { "name": "BGB-26808", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 337, "start_date": "2023-09-21", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05981703" }, { "nct_id": "NCT07554521", "title": "A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Unresectable Gastric Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Advanced Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-04-30", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 8, "location_summary": "Cerritos, California • Los Angeles, California • Coral Springs, Florida + 5 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07554521" }, { "nct_id": "NCT05245760", "title": "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Esophagogastric Junction Cancer" ], "interventions": [ { "name": "Intravenous Tislelizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Fractionated radiation", "type": "RADIATION" }, { "name": "Esophagectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Zhonglin Hao", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2022-04", "completion_date": "2033-12", "has_results": false, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05245760" }, { "nct_id": "NCT06422520", "title": "A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BGB-C354", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2024-07-08", "completion_date": "2026-05-15", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-28T09:50:54.334Z", "location_count": 5, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06422520" } ] }